Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline

Novo Nordisk's experimental heart medicine ziltivekimab failed a clinical trial, CNBC reports. The drug did not achieve statistically significant improvements in major cardiovascular events, marking a setback for the pharmaceutical company's pipeline. The announcement sent Novo shares down nine percent.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton